CanSino Biologics Inc
SSE:688185
CanSino Biologics Inc
SSE:688185
Price:
68.64
CNY
-1.51%
Market Closed
Market Cap:
¥11.1B
Relative Value
The Relative Value of one
CanSino Biologics Inc
stock under the Base Case scenario is
56.81
CNY.
Compared to the current market price of 68.64 CNY,
CanSino Biologics Inc
is
Overvalued by 17%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
56.81
CNY
Overvaluation 17%
Multiples Across Competitors
Competitors Multiples
CanSino Biologics Inc Competitors
CanSino Biologics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
CanSino Biologics Inc
SSE:688185
|
11.1B CNY | 11.5 | -78.4 | -52.9 | -52.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987.6B USD | 16.5 | 53.2 | 35.7 | 38.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
565.6B USD | 6 | 21 | 14.6 | 17.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
280.6B CHF | 4.6 | 30 | 12.7 | 14.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.9B GBP | 5.1 | 31.7 | 15.1 | 22.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.4B CHF | 5.2 | 20.2 | 12.7 | 16.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
291.6B USD | 4.5 | 15 | 10.6 | 12.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK | 5.2 | 15.9 | 11 | 12.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
146.4B USD | 2.3 | 14.9 | 7.6 | 10.3 | |
| FR |
|
Sanofi SA
PAR:SAN
|
97.3B EUR | 1.7 | 8.2 | 7.7 | 7.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
